Alebund Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies primarily targeting kidney diseases and their complications, as well as other chronic conditions. The company emphasizes a science-driven approach to create novel treatments that address significant unmet medical needs in this area. Their pipeline includes advanced products aimed at managing hyperphosphatemia, IgA nephropathy, diabetic kidney disease (DKD), and autosomal dominant polycystic kidney disease (ADPKD). For instance, their lead product, AP301, is designed to effectively bind phosphate without systemic absorption, thereby addressing the complications associated with hyperphosphatemia in chronic kidney disease (CKD) patients.

In addition to AP301, Alebund is developing therapies targeting IgA nephropathy by inhibiting the MASP-2 enzyme, which has shown promising results in clinical trials. Their approach to diabetic kidney disease focuses on renal hemodynamics to mitigate glomerular hyperfiltration, complementing existing treatments like ACE inhibitors and SGLT-2 inhibitors. Furthermore, Alebund is exploring treatments for ADPKD, a genetic disorder that leads to kidney dysfunction, by targeting the underlying mechanisms of the disease. Overall, Alebund Pharmaceuticals is committed to advancing therapeutic options that can significantly improve patient outcomes in kidney-related diseases.

China

Alebund is a clinical stage biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions.

Alebund Pharmaceuticals

Company Details